Halyard Health Inc (HYH) Given Average Rating of “Buy” by Brokerages

Shares of Halyard Health Inc (NYSE:HYH) have been given an average recommendation of “Buy” by the eight research firms that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $47.00.

Several equities analysts have commented on HYH shares. TheStreet upgraded shares of Halyard Health from a “c+” rating to a “b” rating in a research note on Monday, December 4th. ValuEngine upgraded shares of Halyard Health from a “hold” rating to a “buy” rating in a research note on Sunday, December 31st. Zacks Investment Research upgraded shares of Halyard Health from a “hold” rating to a “buy” rating and set a $53.00 price target on the stock in a research note on Wednesday, December 6th. Stifel Nicolaus reiterated a “buy” rating and issued a $52.00 price target on shares of Halyard Health in a research note on Friday, November 3rd. Finally, KeyCorp restated a “hold” rating on shares of Halyard Health in a research report on Tuesday, October 17th.

Shares of Halyard Health (NYSE HYH) traded down $0.61 during trading on Friday, reaching $48.31. 323,051 shares of the company’s stock traded hands, compared to its average volume of 309,854. The stock has a market capitalization of $2,291.24, a price-to-earnings ratio of 40.60, a P/E/G ratio of 2.57 and a beta of 1.71. Halyard Health has a one year low of $35.24 and a one year high of $50.99. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.13 and a quick ratio of 1.19.

Halyard Health (NYSE:HYH) last announced its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.60 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.47 by $0.13. The company had revenue of $401.40 million for the quarter, compared to analyst estimates of $394.54 million. Halyard Health had a net margin of 3.52% and a return on equity of 8.65%. The firm’s revenue was up 1.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.48 earnings per share. sell-side analysts predict that Halyard Health will post 2.08 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Dimensional Fund Advisors LP grew its position in shares of Halyard Health by 5.1% during the third quarter. Dimensional Fund Advisors LP now owns 3,292,483 shares of the medical instruments supplier’s stock worth $148,262,000 after acquiring an additional 159,434 shares during the last quarter. State Street Corp grew its position in shares of Halyard Health by 7.5% during the second quarter. State Street Corp now owns 1,702,423 shares of the medical instruments supplier’s stock worth $66,872,000 after acquiring an additional 119,154 shares during the last quarter. Paradice Investment Management LLC grew its position in shares of Halyard Health by 2.1% during the third quarter. Paradice Investment Management LLC now owns 1,564,813 shares of the medical instruments supplier’s stock worth $70,464,000 after acquiring an additional 31,832 shares during the last quarter. Prudential Financial Inc. grew its position in shares of Halyard Health by 3.9% during the third quarter. Prudential Financial Inc. now owns 686,309 shares of the medical instruments supplier’s stock worth $30,904,000 after acquiring an additional 25,680 shares during the last quarter. Finally, Copper Rock Capital Partners LLC grew its position in shares of Halyard Health by 3.6% during the fourth quarter. Copper Rock Capital Partners LLC now owns 677,184 shares of the medical instruments supplier’s stock worth $31,631,000 after acquiring an additional 23,469 shares during the last quarter. Institutional investors and hedge funds own 89.32% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Halyard Health Inc (HYH) Given Average Rating of “Buy” by Brokerages” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/03/halyard-health-inc-hyh-given-average-rating-of-buy-by-brokerages.html.

About Halyard Health

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply